DLX1 is a homeobox transcription factor that functions as both transcriptional activator and repressor, with critical roles spanning developmental and pathological contexts. During normal development, DLX1 regulates hematopoietic differentiation by inhibiting cytokine signaling pathways including TGF-β, activin-A, and BMP4 through interference with transcriptional factors like SMAD2 and SMAD3 1. DLX1 coordinates hypothalamic neurogenesis, where it specifies GHRH-neuronal identity while suppressing AgRP-neuronal fate through direct repression of Otp expression 2. During forebrain development, DLX1+ GABAergic inhibitory neurons originate from the dorsal neocortex and disperse radially, contributing to forebrain organization 3. In the lateral hypothalamus, DLX1 expression marks GABAergic-rich tuberal regions essential for neural circuit organization 4. DLX1 also maintains epidermal stem cell heterogeneity during aging, with Dlx1+ slow-cycling clones expanding over time 5. Pathologically, DLX1 is significantly overexpressed in lung adenocarcinoma, where elevated expression correlates with advanced stages, TP53 mutations, and poor survival 6, 7. DLX1 drives tumorigenesis by transcriptionally activating NCS1, which in turn promotes MYC-dependent oncogenic pathways 6. Additionally, PERK haplotype B selectively permits DLX1 translation during the unfolded protein response, promoting tau toxicity in progressive supranuclear palsy pathogenesis 8.